Investigational Agents for Relapsed/Refractory MyelomaAugust 24th 2021
Keith Stewart, MD, ChB, MBA; Sagar Lonial, MD, FACP; Cristina Gasparetto, MD; Joseph Mikhael, MD; and Nina Shah, MD, review additional emerging agents in the pipeline for the treatment of RRMM; including BCMA-targeted bispecific antibodies.
CASSIOPEIA Trial of Dara-VTd in Transplant-Eligible MyelomaAugust 3rd 2021
Joseph Mikhael, MD, reviews updated results presented at the 2021 ASCO annual meeting of the phase 3 CASSIOPEIA trial for NDMM, and Nina Shah, MD, comments on how the data may inform the addition of daratumumab to triplet therapy at relapse.
Improving Maintenance Therapy for MyelomaJuly 20th 2021
Multiple myeloma experts share their thoughts on improving on currently available maintenance therapy, particularly for high-risk patients, and review their personal approaches to maintenance therapy for standard- and high-risk disease.
Overview of Newly Diagnosed Multiple MyelomaJuly 13th 2021
Keith Stewart, MD, ChB, MBA; Sagar Lonial, MD, FACP; Cristina Gasparetto, MD; Joseph Mikhael, MD; and Nina Shah, MD, discuss the diagnostic work-up for a patient with newly diagnosed multiple myeloma and the impact of age and frailty scores on transplant eligibility.